In a study dedicated to exploring the perceptions around magic mushrooms in Canada, nearly 80% of participants expressed their opinion that psilocybin should be accessible for medical treatment to those in distress. Moreover, approximately two-thirds of the Canadian respondents from the same study concurred that psilocybin should be legally obtainable for those who require it.
Along with advocating for the increased accessibility of this substance, a significant number of participants, about 84.8 percent, believe that the public health system should bear the costs of such treatments. A majority of Canadians see psilocybin as a practical alternative, especially for managing end-of-life distress.
[toc]
Main Takeaways:
- Residents from Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical option for dealing with end-of-life existential distress.
- Magic mushrooms are seen as safe for the treatment of existential distress.
- Participants in two double-blind studies reported immediate and sustained benefits, with effects persisting for six months or longer.
Understanding Existential Distress
Existential distress, closely related to existential suffering, spiritual distress, and demoralization, arises when individuals are faced with their mortality. Patients can experience feelings of helplessness, isolation, anxiety, and a loss of purpose and meaning in life. This distress particularly impacts patients with life-threatening illnesses, potentially leading to thoughts of hastening death or contemplating suicide.
Commonly, individuals grappling with terminal illnesses or significant life changes are those who experience this type of distress. It severely impacts their mental health and overall life quality.
Existential therapy aims to tackle issues such as anxiety, depression, grief, loneliness, indifference, despair, confusion about identity, feelings of purposelessness, and existential fear. These sessions might be numerous and may not yield positive results for everyone.
The doubts regarding the effectiveness of such therapy is a primary factor driving many individuals to seek alternative treatments.
The Stance of Health Canada on Psilocybin as a Therapeutic Option
In the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances for tackling complex mental disorders. Specifically, psilocybin has demonstrated a quick and long-lasting relief from existential distress in terminal patients.
Recognizing the possible effectiveness of these proposed hallucinogenic mushrooms, particularly when standard treatments are ineffective, Health Canada revised the Special Access Program in 2022. This revision permits healthcare providers to apply for controlled substances on behalf of their patients.
Canadian Support for Access to Psilocybin
A study published in the Palliative Care Journal investigates public views on psilocybin-assisted therapy for end-of-life care. The data collected in the study includes:
| Methodology | Engagement from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia, 19% of them are previous psilocybin users (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress, 63.3% think psilocybin should be integrated into medical treatments, 84.8% endorse the public health system’s offering of this therapy, and 44.2% believe healthcare providers should administer the substance without Health Canada’s supervision. |
The findings align with surveys conducted in Canada, England, and Australia. The researchers stressed the uniqueness of their study as it focuses on the use of psychoactive substances for addressing existential distress in end-of-life situations.
Rationale Behind Canadian Support for Psilocybin Use
An increasing number of Canadians are welcoming the use of psilocybin as a treatment, primarily driven by robust findings from esteemed research institutions. The perceived safety of psilocybin mushrooms in easing existential distress is another influential factor. No severe adverse health effects, such as multi-organ failure, have been reported by subjects across various studies.
| Study | Approach | Outcomes | |
| Johns Hopkins Study | 51 patients received a high psilocybin dose and a low dose as an active placebo control | Immediate and long-term | The benefits of the therapy can last up to six months or even longer. The effectiveness of the therapy is largely due to mystical experiences that promote a sense of unity and deep emotional insights. |
| Trial at New York University | 29 patients were randomly chosen to receive either psilocybin or the active placebo, niacin | The results of this study echoed those of the Johns Hopkins study. Participants who received psilocybin reported psychological relief along with an improved outlook on life and death. | |
| BMC Palliative Care | The study interviewed nineteen participants, including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and 1 psychologist, aiming to understand how palliative care professionals perceive existential distress and their opinions on psychedelic therapy as a treatment option. | As per the palliative care professionals, psychedelic-assisted therapy (PAT) shows promise in alleviating existential distress. |
Patient Experiences
Beyond scientific studies, several patient stories also support the effectiveness of psilocybin, highlighting its potential to improve mental health and the quality of life.
The Journey of Yokoi
Mio Yokoi, who was battling terminal stage 4 pancreatic cancer, shares a transformative experience during her assisted therapy. She envisions herself on a raft, surrounded by nature and whimsical creatures, developing a profound understanding of her connection with the universe and feeling a sense of immense peace and affirmation.
Despite receiving conventional mental health support, Yokoi struggled with severe anxiety and distress following her diagnosis. Psilocybin therapy helped her reconnect with her body and provided a tangible sense of love and support, significantly improving her emotional and mental wellbeing.
The Story of Chrissy
Chrissy, a woman in her 50s, was battling stage 4 breast cancer, which had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare at the time of the study and identified herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in her anxiety, depression, fear of death, feelings of hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs since her therapy session, she expressed that the experiences had brought a sense of purpose and reality to her beliefs.
Brenda’s Journey
During her therapy sessions, Brenda experienced the sensation of dying twice. These experiences transformed her fear of death into an acceptance of it as a natural part of life. She attributed her healing from childhood trauma to the therapy, a change that was also reflected in her data. The therapy also led to a decrease in her anxiety and fear of death, while her spiritual awareness increased.
Availability of Magic Mushroom Products in Canada
The access to psilocybin capsules and other related products designed to ease existential distress or other mental health conditions may be limited at present. However, reliable online dispensaries can provide these products when needed.
| Characteristics | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some other South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Related to the Penis Envy mushroom strain, which rose to fame in the 1970s. |
| Potency | Moderate potency, suitable for beginners. | Moderate potency as well, ideal for first-timers. | Highly potent, recommended for those with some experience. |
| Effects | Causes a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Triggers an energizing and long-lasting high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal imagery, and feelings of happiness. | Induces deep shamanic experiences, vision quests, intense mystical experiences, heightened creativity, focus, social awareness, and mood enhancement. |
Using Psilocybin Products to Ease End-of-life Distress
Dealing with end-of-life or existential distress can be extremely challenging for patients nearing the end of their lives. Traditional methods of addressing this distress often prove insufficient, resulting in a growing demand within Canada for easier access to magic mushrooms in the public healthcare system. This increasing public interest could We urge regulatory authorities to explore the potential of magic mushrooms as an effective treatment option. Get your psychedelics and shroom delivery from Magic Mushroom Delivery Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
The outcome of Psychedelic-assisted therapy (PAT) can differ greatly between patients, and following specific steps and thorough preparation is crucial for a positive outcome. Prior to ingestion, patients must undertake comprehensive screening and mental readiness.
- Preparation for the Session: An in-depth evaluation of patients is carried out. The therapist discusses the patients’ goals and expectations to set intentions for the session. The therapist also explains the implications of the process and what the patient can expect during the session.
- The Session: During the session, a controlled dose of the substance is administered to patients in a quiet, comfortable environment to promote relaxation and introspection. The therapist provides constant guidance and support throughout.
- Post-Session Integration Therapy: This therapy helps patients make sense of their experiences. Follow-up sessions provide ongoing support and counselling to reinforce the insights and transformations gained during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, particularly the 5-HT2A receptor. This interaction can cause perceptual, mood, and cognitive changes, leading to significant shifts in consciousness, emotional breakthroughs, and new viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not suited for everyone. Patients with certain mental health conditions or existential distress are thoroughly screened to rule out those with a history of psychosis.
Related Reads:
